Bessemer Group’s vTv Therapeutics VTVT Stock Holding History

Bessemer Group’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4K	Hold	112	–	–	﹤0.01%	2288
2025 Q4	$4K	Buy	+112	New	+$3.12K	﹤0.01%	2308

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Bessemer Group's VTVT Position: Q1 2026 in Review

Bessemer Group held its vTv Therapeutics (VTVT) position steady in Q1 2026 at 112 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Bessemer Group first reported a position in VTVT in Q4 2025 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

Bessemer Group held 112 shares of vTv Therapeutics worth $4K as of Q1 2026.
Bessemer Group left its vTv Therapeutics share count unchanged in Q1 2026.
vTv Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2288 holding.
Bessemer Group first reported a position in vTv Therapeutics in Q4 2025 and has held it in 2 quarters since.
35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.